Upload
fahim
View
24
Download
1
Embed Size (px)
DESCRIPTION
Dr Adrian Bloor Transplant Director. Transplantation in Lymphoma. Are you a believer?. Transplant Outcomes. Summary. A big subject in 20 mins Briefly review rationale for transplantation Autografting Historical results and place in current treatment New data in DLBCL, MCL - PowerPoint PPT Presentation
Citation preview
Transplantation in Lymphoma
Dr Adrian BloorTransplant Director
The Christie NHS Foundation Trust
NHSNHS
Are you a believer?
The Christie NHS Foundation Trust
NHSNHS
Transplant Outcomes
The Christie NHS Foundation Trust
NHSNHS
Summary
• A big subject in 20 mins
• Briefly review rationale for transplantation
• Autografting Historical results and place in current treatment
New data in DLBCL, MCL
• Allografting Follicular NHL
Hodgkin Lymphoma
The Christie NHS Foundation Trust
NHSNHS
Autologous Transplantation
The Christie NHS Foundation Trust
NHSNHS
Dose intensity
Cou
nt
Time
Blood countDisease
Cou
nt
The Christie NHS Foundation Trust
NHSNHS
Autologous Transplantation
Indication TrialMedian PFS
months
OS
months
Relapsed FL CUP >36 vs 12 NR vs 46
Transformed FL EBMT NS (vs controls) NS (vs controls)
MCL MCL Network 39 vs 17 NS
Relapsed DLBCL PARMA >48 vs <12 NR vs 15
Relapsed HL BNLI/GHDSG >36 vs <12 NS
Williams CD et al J Clin Oncol 2001;19:727Shouten HC et al J Clin Oncol 2003;21:3918Dreyling M et al Blood 2005;105:2677Philip T et al N Engl J Med 1995;333:1540Schmitz N et al Lancet 2002;359:2065Linch DC et al Lancet 1993;341:8852
The Christie NHS Foundation Trust
NHSNHS
CORAL - DLBCL
Gisselbrecht C et al J Clin Oncol 2009;27:8509a
n = 396• Response rate 63% • Relapse < 12 months (46% vs 88%) • Prior Rituxumab (51% vs 83%)
Relapsed DLBCL
R-ICE
R-DHAP
BEAM
RANDOMISE
Observe
R maint
RANDOMISE
The Christie NHS Foundation Trust
NHSNHS
CORAL - DLBCL
n = 123
3 year OS/EFS 47/30%
PET –ve
OS 66%EFS 40%
Trneny M et al Blood 2009;114:881a
The Christie NHS Foundation Trust
NHSNHS
CORAL - DLBCL
n = 123
3 year OS/EFS 47/30%
PET –ve
OS 66%EFS 40%
PET +ve
OS 49%EFS 16%
p = sig
Trneny M et al Blood 2009;114:881a
The Christie NHS Foundation Trust
NHSNHS
Mantle Cell Lymphoma - Nordic
n = 41
ORR 75% CR 27%
4 yr PFS 15%
n = 160
ORR 96% CR 54%
6 yr PFS 66%
NRM 5%
Z-BEAM (no CR)
MCL 32006-2009
n = 160
ORR 96% CR 68%
NRM 4%
maxi-CHOPx4
BEAM(C) auto
MCL 11996-2000
R-maxi-CHOP /R-HD-AraC x6
Purged BEAM(C) auto
R
MCL 22000-2006
Andersen NC et al Eur J Haematol 2003;71:73 Geisler CH et al Blood 2008;112:2687 Kolstad A et al Blood 2009;114:932a
The Christie NHS Foundation Trust
NHSNHS
Autograft mortality 1998-2002
SUM05_20.ppt
Infection (6%)
Other (9%)
Organ toxicity (8%)Relapse (75%)
Unknown (2%)
The Christie NHS Foundation Trust
NHSNHS
Allogeneic Transplantation
derived from Bortin MM Transplantation 1970;9:571
The Christie NHS Foundation Trust
NHSNHS
Beneficial effect of GvHD
Horowitz MM et al Blood 1990;75:555
The Christie NHS Foundation Trust
NHSNHS
RECIPIENT DONOR
GvD
GvHD and GvDisease
The Christie NHS Foundation Trust
NHSNHS
RECIPIENT DONOR
GvD
GvHD and GvDisease
The Christie NHS Foundation Trust
NHSNHS
GvHD and GvDisease
0.00001
0.0001
0.001
0.01
0.1
1
Jun-09 Sep-09 Dec-09 Mar-10 Jun-10 Sep-10
Chemo SCT
CSA
The Christie NHS Foundation Trust
NHSNHS
Follicular NHL
Series Follow up n Protocol PFS/OS NRMExtensive
cGvHD
UCLH 43 mo 82 FMC90% (sib)
64% (UD)
8% (sib)
22% (UD)18%
MDACC 60 mo 43 FCR 85% 16% 36%
Thomson KJ et al J Clin Oncol 2010;28:3695Khouri IF et al Blood 2008;111:5530
Montoto S et al Leukemia 2007;21:2324
Replacement for autograft?
The Christie NHS Foundation Trust
NHSNHS
HL: Winners and Losers
The Christie NHS Foundation Trust
NHSNHS
HL: Salvage autografts
Schmitz N et al Lancet 2002;359:2065Linch DC et al Lancet 1993;341:8852
The Christie NHS Foundation Trust
NHSNHS
MSKCC
• 71 patients (1994-2005)• Poor prognosis• Second transplant improves
outcome
And if it doesn’t work?
Moskowitz AJ Br J Haematol 2009;146:158
The Christie NHS Foundation Trust
NHSNHS
AlloHSCT for poor prognosis?
The Christie NHS Foundation Trust
NHSNHS
AlloHSCT for poor prognosis?
Milied N et al J Clin Oncol 1996;14:1291
EMBT matched pair series
• 90 patients• >50% refractory relapse• 2 yr NRM >50% (allo) vs 12% (auto)
But..
• GvHD appears beneficial• Relapse rate 13% (allo) vs 69% (auto)
The Christie NHS Foundation Trust
NHSNHS
RIC Allo outcome
Centre nPrior HDT
RefractoryPFS
(2-4 yr)
OS
(2-4 yr)
EBMT 401 67% 22% 26% (3 yr) 41% (3yr)
Single Centre
32-5871-
100%33-50% 8-39% 32-64%
NRM 12-46% Age, PS, date of transplant
Robinson SP et al Haematologica 2009;94:230
The Christie NHS Foundation Trust
NHSNHS
Pick a winner
TTF – based on prognostic score
• PS• Disease Status• Chemosensitivity• Remission duration• Tumour bulk • Extranodal disease
eg Stanford series
Johnston LJ et al Biol Blood Marrow Trans 2000;6:289
0
1
32
The Christie NHS Foundation Trust
NHSNHS
Pick a winner
Patient A Patient B
The Christie NHS Foundation Trust
NHSNHS
Risk Stratification by FI
Centre n Technique3 yr EFS
PET +ve
3 yr EFS
PET -ve
MDACC 21168 PET 174 Ga
27%52% (PR)
77% (CR)
MSKCC 16050 PET 110 Ga
33% 74%
Jabbour E et al Cancer 2007;109:2481Moskowitz C unpublished
The Christie NHS Foundation Trust
NHSNHS
Trials
The Christie NHS Foundation Trust
NHSNHS
Trials designed
ReACH
• Chemosensitive PET +ve second remission
• Siblings donors
PAIReD
• Chemorefractory (PET) first or second remission
• Matched donors
The Christie NHS Foundation Trust
NHSNHS
Patient Selection
Extermann M et al Eur J Can 2000;36:453Havlik R et al Cancer 1994;74(s7):2101http://seer.cancer.gov/
Comorbidities by age
0
20
40
60
80
100
55-64 65-74 75+
Age range / yearsF
requ
ency
/ %
≤1 2-4 ≥5
0
100
0 20 40 60 80Age
Inci
denc
e / 1
00,0
00
The Christie NHS Foundation Trust
NHSNHS
Conclusions
• A big subject in 20 mins
• Autologous transplant effective treatment for many patients with relapsed disease
• Autografts have no potential for cure
• Allogeneic effect exists in lymphoma
• Allogeneic transplantation remains developmental in most areas
• Ongoing trials in progress
• Patient selection essential – but how?